IP Library Granted Patent US 7,402,672
Granted Patent B2
US 7,402,672 · App. 11/001,533 · Granted Jul 22, 2008

Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,402,672
App. No.
11/001,533
Granted
Jul 22, 2008
Kind
B2
Abstract

The present invention discloses and claims compounds of formula (I) as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.

Claims (59)

1. A compound of formula (I)

wherein:

R 1 is H or C 1-6 alkyl;

R 2 is NR 5 R 6 ;

R 3 is aryl or heterocycle;

R 4 is H, C 1-6 alkyl, C 1-6 alkoxy, CF 3 , halogen, S—C 1-6 alkyl, —SH, —NH 2 or NR 5 R 6 ;

R 5 is H or C 1-6 alkyl;

R 6 is H or C 1-6 alkyl.

2. The compound according to claim 1 wherein R 1 is H or C 1-6 alkyl, R 5 is H, R 6 is H or C 1-6 alkyl, and R 3 is aryl.

3. The compound according to claim 2 selected from the group consisting of:1-methyl-3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid methylamide, 1-methyl-3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, and 3-phenylsulfanyl-1-propyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide.

4. The compound according to claim 1 wherein R 1 , R 4 and R 5 are each H, R 3 is aryl and R 6 is C 1-6 alkyl.

5. The compound according to claim 4 selected from the group consisting of:

3-(3-trifluoromethyoxyphenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid methylamide,

3-(3-chlorophenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid methylamide,

3-(3-fluorophenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid methylamide, and

3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid methylamide.

6. The compound according to claim 1 wherein R 1 , R 4 , R 5 and R 6 is each H and R 3 is heterocycle.

7. The compound according to claim 6 is selected from the group consisting of:

3-(quinolin-8-ylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(pyridin-2-sulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(pyridin-4-sulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, and

3-(thiophen-2-ylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide.

8. The compound according to claim 6 wherein R 1 , R 5 and R 6 are each H and R 3 is aryl.

9. The compound according to claim 1 selected from the group consisting of:

3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(3-fluorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(3-chlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(3-bromophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(2-chlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(4-chlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(2,4-dichlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(2-fluorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(2,3-dichlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(2-trifluormethylphenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(3-trifluoromethyl-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(2-aminophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(2,5-dichloro-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(2-methoxy-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(3-methoxy-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(3-amino-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(4-nitro-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(3-nitro-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-o-tolylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-p-tolylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(3,5-dimethyl-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-m-tolylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(2-ethyl-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide,

3-(3-trifluoromethoxy-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid, amide,

3-(3-fluoro-phenylsulfanyl)-5-methoxy-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, and

3-(3-methoxy-phenylsulfanyl)-5-methoxy-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide.

10. A pharmaceutical composition comprising one or more pharmaceutical carriers and a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, of formula (I):

wherein:

R 1 is H or C 1-6 alkyl;

R 2 is NR 5 R 6 ;

R 3 is aryl or heterocycle;

R 4 is H, C 1-6 alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 1-6 alkoxy, CF 3 , halogen,

SH, S—C 1-6 alkyl, NO 2 , NH 2 or NR 5 R 6 ;

R 5 is H or C 1-6 alkyl;

R 6 is H or C 1-6 alkyl.

11. The pharmaceutical composition of claim 10 wherein said pharmaceutical carrier is selected from the group consisting of diluents, binders, solvents, disintegrating agents, lubricants, sweetening agents, bulking agents, permeation enhancers, and solvents.

Assignments (5)
MERGER Recorded Jan 19, 2015
From: AVENTIS PHARMACEUTICALS INC.
To: AVENTISUB LLC
Reel/Frame 034781/0334 →
CERTIFICATE OF CONVERSION Recorded Dec 9, 2014
From: AVENTISUB INC.
To: AVENTISUB LLC
Reel/Frame 034566/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2008
From: METZ, WILLIAM ARTHUR, JR.; CHOI-SLEDESKI, YONG MI; POLI, GREGORY BERNARD; CHIANG, YULIN; FINK, DAVID MARC; HUANG, BAO-GUO; GELORMINI, ANN MARIE; GAMBOA, JUAN ANTONIO; GIOVANNI, ANDREW; ROEHR, JOACHIM E.; TSAY, JOSEPH I.; CAMACHO, FERNANDO; HURST, WILLIAM JOSEPH; HARNISH, STEPHEN WAYNE
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 020953/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2008
From: HALLEY, FRANK; DUTRUC-ROSSET, GILLES; DOERFLINGER, GILLES
To: AVENTIS PHARMA S.A..
Reel/Frame 020953/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2008
From: AVENTIS PHARMA S.A.
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 020953/0422 →